Down-regulation of the brain-specific cell-adhesion molecule contactin-3 in tuberous sclerosis complex during the early postnatal period / Anatoly KOROTKOV in Journal of Neurodevelopmental Disorders, 14 (2022)  

Public ISBD [article]  inJournal of Neurodevelopmental Disorders > 14 (2022) Titre : Down-regulation of the brain-specific cell-adhesion molecule contactin-3 in tuberous sclerosis complex during the early postnatal period Type de document : texte imprimé Auteurs : Anatoly KOROTKOV, Auteur ; Mark J. LUINENBURG, Auteur ; Alessia ROMAGNOLO, Auteur ; Till S. ZIMMER, Auteur ; Jackelien VAN SCHEPPINGEN, Auteur ; Anika BONGAARTS, Auteur ; Diede W.M. BROEKAART, Auteur ; Jasper J. ANINK, Auteur ; Caroline MIJNSBERGEN, Auteur ; Floor E. JANSEN, Auteur ; Wim VAN HECKE, Auteur ; Wim G. SPLIET, Auteur ; Peter C. VAN RIJEN, Auteur ; Martha FEUCHT, Auteur ; Johannes A. HAINFELLNER, Auteur ; Pavel KRSEK, Auteur ; Josef ZAMECNIK, Auteur ; Peter B. CRINO, Auteur ; Katarzyna KOTULSKA, Auteur ; Lieven LAGAE, Auteur ; Anna C. JANSEN, Auteur ; David J.. KWIATKOWSKI, Auteur ; Sergiusz JOZWIAK, Auteur ; Paolo CURATOLO, Auteur ; Angelika MÃœHLEBNER, Auteur ; Erwin A. VAN VLIET, Auteur ; James D. MILLS, Auteur ; Eleonora ARONICA, Auteur Langues : Anglais (eng) Mots-clés : Adolescent  Adult  Autism Spectrum Disorder/complications/metabolism  Brain/metabolism  Child  Child, Preschool  Contactins/genetics/metabolism  Down-Regulation  Humans  Infant  Infant, Newborn  Middle Aged  Tuberous Sclerosis/complications/metabolism  Young Adult  Cell adhesion  Cerebral cortex development  Epilepsy  Neurodevelopmental disorders  mTORopathies Index. décimale : PER Périodiques Résumé : BACKGROUND: The genetic disorder tuberous sclerosis complex (TSC) is frequently accompanied by the development of neuropsychiatric disorders, including autism spectrum disorder and intellectual disability, with varying degrees of impairment. These co-morbidities in TSC have been linked to the structural brain abnormalities, such as cortical tubers, and recurrent epileptic seizures (in 70-80% cases). Previous transcriptomic analysis of cortical tubers revealed dysregulation of genes involved in cell adhesion in the brain, which may be associated with the neurodevelopmental deficits in TSC. In this study we aimed to investigate the expression of one of these genes - cell-adhesion molecule contactin-3. METHODS: Reverse transcription quantitative polymerase chain reaction for the contactin-3 gene (CNTN3) was performed in resected cortical tubers from TSC patients with drug-resistant epilepsy (n = 35, age range: 1-48 years) and compared to autopsy-derived cortical control tissue (n = 27, age range: 0-44 years), as well as by western blot analysis of contactin-3 (n = 7 vs n = 7, age range: 0-3 years for both TSC and controls) and immunohistochemistry (n = 5 TSC vs n = 4 controls). The expression of contactin-3 was further analyzed in fetal and postnatal control tissue by western blotting and in-situ hybridization, as well as in the SH-SY5Y neuroblastoma cell line differentiation model in vitro. RESULTS: CNTN3 gene expression was lower in cortical tubers from patients across a wide range of ages (fold change = - 0.5, p < 0.001) as compared to controls. Contactin-3 protein expression was lower in the age range of 0-3 years old (fold change = - 3.8, p < 0.001) as compared to the age-matched controls. In control brain tissue, contactin-3 gene and protein expression could be detected during fetal development, peaked around birth and during infancy and declined in the adult brain. CNTN3 expression was induced in the differentiated SH-SY5Y neuroblastoma cells in vitro (fold change = 6.2, p < 0.01). CONCLUSIONS: Our data show a lower expression of contactin-3 in cortical tubers of TSC patients during early postnatal period as compared to controls, which may affect normal brain development and might contribute to neuropsychiatric co-morbidities observed in patients with TSC. En ligne : https://dx.doi.org/10.1186/s11689-022-09416-2 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=574 [article] Down-regulation of the brain-specific cell-adhesion molecule contactin-3 in tuberous sclerosis complex during the early postnatal period [texte imprimé] / Anatoly KOROTKOV, Auteur ; Mark J. LUINENBURG, Auteur ; Alessia ROMAGNOLO, Auteur ; Till S. ZIMMER, Auteur ; Jackelien VAN SCHEPPINGEN, Auteur ; Anika BONGAARTS, Auteur ; Diede W.M. BROEKAART, Auteur ; Jasper J. ANINK, Auteur ; Caroline MIJNSBERGEN, Auteur ; Floor E. JANSEN, Auteur ; Wim VAN HECKE, Auteur ; Wim G. SPLIET, Auteur ; Peter C. VAN RIJEN, Auteur ; Martha FEUCHT, Auteur ; Johannes A. HAINFELLNER, Auteur ; Pavel KRSEK, Auteur ; Josef ZAMECNIK, Auteur ; Peter B. CRINO, Auteur ; Katarzyna KOTULSKA, Auteur ; Lieven LAGAE, Auteur ; Anna C. JANSEN, Auteur ; David J.. KWIATKOWSKI, Auteur ; Sergiusz JOZWIAK, Auteur ; Paolo CURATOLO, Auteur ; Angelika MÃœHLEBNER, Auteur ; Erwin A. VAN VLIET, Auteur ; James D. MILLS, Auteur ; Eleonora ARONICA, Auteur. Langues : Anglais (eng) in Journal of Neurodevelopmental Disorders > 14 (2022) Mots-clés : Adolescent  Adult  Autism Spectrum Disorder/complications/metabolism  Brain/metabolism  Child  Child, Preschool  Contactins/genetics/metabolism  Down-Regulation  Humans  Infant  Infant, Newborn  Middle Aged  Tuberous Sclerosis/complications/metabolism  Young Adult  Cell adhesion  Cerebral cortex development  Epilepsy  Neurodevelopmental disorders  mTORopathies Index. décimale : PER Périodiques Résumé : BACKGROUND: The genetic disorder tuberous sclerosis complex (TSC) is frequently accompanied by the development of neuropsychiatric disorders, including autism spectrum disorder and intellectual disability, with varying degrees of impairment. These co-morbidities in TSC have been linked to the structural brain abnormalities, such as cortical tubers, and recurrent epileptic seizures (in 70-80% cases). Previous transcriptomic analysis of cortical tubers revealed dysregulation of genes involved in cell adhesion in the brain, which may be associated with the neurodevelopmental deficits in TSC. In this study we aimed to investigate the expression of one of these genes - cell-adhesion molecule contactin-3. METHODS: Reverse transcription quantitative polymerase chain reaction for the contactin-3 gene (CNTN3) was performed in resected cortical tubers from TSC patients with drug-resistant epilepsy (n = 35, age range: 1-48 years) and compared to autopsy-derived cortical control tissue (n = 27, age range: 0-44 years), as well as by western blot analysis of contactin-3 (n = 7 vs n = 7, age range: 0-3 years for both TSC and controls) and immunohistochemistry (n = 5 TSC vs n = 4 controls). The expression of contactin-3 was further analyzed in fetal and postnatal control tissue by western blotting and in-situ hybridization, as well as in the SH-SY5Y neuroblastoma cell line differentiation model in vitro. RESULTS: CNTN3 gene expression was lower in cortical tubers from patients across a wide range of ages (fold change = - 0.5, p < 0.001) as compared to controls. Contactin-3 protein expression was lower in the age range of 0-3 years old (fold change = - 3.8, p < 0.001) as compared to the age-matched controls. In control brain tissue, contactin-3 gene and protein expression could be detected during fetal development, peaked around birth and during infancy and declined in the adult brain. CNTN3 expression was induced in the differentiated SH-SY5Y neuroblastoma cells in vitro (fold change = 6.2, p < 0.01). CONCLUSIONS: Our data show a lower expression of contactin-3 in cortical tubers of TSC patients during early postnatal period as compared to controls, which may affect normal brain development and might contribute to neuropsychiatric co-morbidities observed in patients with TSC. En ligne : https://dx.doi.org/10.1186/s11689-022-09416-2 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=574

International consensus recommendations for the identification and treatment of tuberous sclerosis complex-associated neuropsychiatric disorders (TAND) / Petrus J. DE VRIES in Journal of Neurodevelopmental Disorders, 15 (2023)  

Public ISBD [article]  inJournal of Neurodevelopmental Disorders > 15 (2023) Titre : International consensus recommendations for the identification and treatment of tuberous sclerosis complex-associated neuropsychiatric disorders (TAND) Type de document : texte imprimé Auteurs : Petrus J. DE VRIES, Auteur ; Tosca-Marie HEUNIS, Auteur ; Stephanie VANCLOOSTER, Auteur ; Nola CHAMBERS, Auteur ; Stacey BISSELL, Auteur ; Anna W. BYARS, Auteur ; Jennifer FLINN, Auteur ; Tanjala T. GIPSON, Auteur ; Agnies M. VAN EEGHEN, Auteur ; Robert WALTEREIT, Auteur ; Jamie K. CAPAL, Auteur ; Sebastián CUKIER, Auteur ; Peter E. DAVIS, Auteur ; Catherine SMITH, Auteur ; J. Chris KINGSWOOD, Auteur ; Eva SCHOETERS, Auteur ; Shoba SRIVASTAVA, Auteur ; Megumi TAKEI, Auteur ; Sugnet GARDNER-LUBBE, Auteur ; Aubrey J. KUMM, Auteur ; Darcy A. KRUEGER, Auteur ; Mustafa SAHIN, Auteur ; Liesbeth DE WAELE, Auteur ; Anna C. JANSEN, Auteur Langues : Anglais (eng) Mots-clés : Humans  Affect  Anxiety  Autistic Disorder  Consensus  Tuberous Sclerosis/complications/diagnosis/therapy  Consensus recommendations  Education  Mental health  Neurodevelopmental disability  Rare genetic disorders  Tand  Tuberous sclerosis complex  sponsored by Novartis, was on the scientific advisory group of the TOSCA  international disease registry sponsored by Novartis, and has provided  consultancy to GW Pharma. SB is funded by Cerebra to investigate sleep and  behavior in rare genetic syndromes, including TSC. AVE is on the scientific  advisory board and received grant support from Jazz Pharmaceuticals. JC receives  grant funding from the NIH and the Department of Defense for projects related to  TSC. PD receives partial salary support from the NIH for participation in studies  related to TSC, as well as from Aucta Pharmaceuticals for a study of topical  sirolimus for facial angiofibromas in TSC and Marinus Pharmaceuticals for a study  of ganaxolone for TSC‑related epilepsy. CS receives salary support from the TSC  Alliance, a non‑profit organization that reports revenue from individual donors  and corporations including Greenwich Biosciences, GW Pharma, Mallinckrodt,  Nobelpharma, Novartis, Ovid, UCB, and Upsher‑Smith. DAK reports grants from the  National Institutes of Health (NINDS) during the conduct of the study as well as  the personal fees from Novartis Pharmaceuticals, personal fees from Greenwich  Bioscience, grants from Marinus Pharmaceuticals, personal fees from Nobelpharma  America, personal fees from REGENXBIO, and grants and non‑financial support from  TSC Alliance outside the submitted work. MS reports grant support from Novartis,  Biogen, Astellas, Aeovian, Bridgebio, and Aucta and has served on Scientific  Advisory Boards for Novartis, Roche, Regenxbio, SpringWorks Therapeutics, Jaguar  Therapeutics, and Alkermes. ACJ was on the scientific advisory group of the TOSCA  international disease registry sponsored by Novartis and has provided consultancy  to GW Pharma. The remaining authors declared no competing interests. Index. décimale : PER Périodiques Résumé : BACKGROUND: Tuberous sclerosis complex (TSC) is associated with a wide range of physical manifestations for which international clinical recommendations for diagnosis and management have been established. TSC is, however, also associated with a wide range of TSC-Associated Neuropsychiatric Disorders (TAND) that are typically under-identified and under-treated yet associated with a profound burden of disease. The contemporary evidence base for the identification and treatment of TAND is much more limited and, to date, consensus recommendations for the diagnosis and management of TAND have also been limited and non-specific. METHODS: The TANDem project was launched with an international, interdisciplinary, and participatory consortium of 24 individuals, including TSC family representatives, from all World Health Organization (WHO) regions but one. One of the aims of the TANDem project was to generate consensus recommendations for the identification and treatment of TAND. At the time of this project, no internationally adopted standard methodology and methodological checklists existed for the generation of clinical practice recommendations. We therefore developed our own systematic procedure for evidence review and consensus-building to generate evidence-informed consensus recommendations of relevance to the global TSC community. RESULTS: At the heart of the consensus recommendations are ten core principles surrounded by cluster-specific recommendations for each of the seven natural TAND clusters identified in the literature (autism-like, dysregulated behavior, eat/sleep, mood/anxiety, neuropsychological, overactive/impulsive, and scholastic) and a set of wraparound psychosocial cluster recommendations. The overarching recommendation is to "screen" for TAND at least annually, to "act" using appropriate next steps for evaluation and treatment, and to "repeat" the process to ensure early identification and early intervention with the most appropriate biological, psychological, and social evidence-informed approaches to support individuals with TSC and their families. CONCLUSIONS: The consensus recommendations should provide a systematic framework to approach the identification and treatment of TAND for health, educational, social care teams and families who live with TSC. To ensure global dissemination and implementation of these recommendations, partnerships with the international TSC community will be important. One of these steps will include the generation of a "TAND toolkit" of "what to seek" and "what to do" when difficulties are identified in TAND clusters. En ligne : https://dx.doi.org/10.1186/s11689-023-09500-1 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=575 [article] International consensus recommendations for the identification and treatment of tuberous sclerosis complex-associated neuropsychiatric disorders (TAND) [texte imprimé] / Petrus J. DE VRIES, Auteur ; Tosca-Marie HEUNIS, Auteur ; Stephanie VANCLOOSTER, Auteur ; Nola CHAMBERS, Auteur ; Stacey BISSELL, Auteur ; Anna W. BYARS, Auteur ; Jennifer FLINN, Auteur ; Tanjala T. GIPSON, Auteur ; Agnies M. VAN EEGHEN, Auteur ; Robert WALTEREIT, Auteur ; Jamie K. CAPAL, Auteur ; Sebastián CUKIER, Auteur ; Peter E. DAVIS, Auteur ; Catherine SMITH, Auteur ; J. Chris KINGSWOOD, Auteur ; Eva SCHOETERS, Auteur ; Shoba SRIVASTAVA, Auteur ; Megumi TAKEI, Auteur ; Sugnet GARDNER-LUBBE, Auteur ; Aubrey J. KUMM, Auteur ; Darcy A. KRUEGER, Auteur ; Mustafa SAHIN, Auteur ; Liesbeth DE WAELE, Auteur ; Anna C. JANSEN, Auteur. Langues : Anglais (eng) in Journal of Neurodevelopmental Disorders > 15 (2023) Mots-clés : Humans  Affect  Anxiety  Autistic Disorder  Consensus  Tuberous Sclerosis/complications/diagnosis/therapy  Consensus recommendations  Education  Mental health  Neurodevelopmental disability  Rare genetic disorders  Tand  Tuberous sclerosis complex  sponsored by Novartis, was on the scientific advisory group of the TOSCA  international disease registry sponsored by Novartis, and has provided  consultancy to GW Pharma. SB is funded by Cerebra to investigate sleep and  behavior in rare genetic syndromes, including TSC. AVE is on the scientific  advisory board and received grant support from Jazz Pharmaceuticals. JC receives  grant funding from the NIH and the Department of Defense for projects related to  TSC. PD receives partial salary support from the NIH for participation in studies  related to TSC, as well as from Aucta Pharmaceuticals for a study of topical  sirolimus for facial angiofibromas in TSC and Marinus Pharmaceuticals for a study  of ganaxolone for TSC‑related epilepsy. CS receives salary support from the TSC  Alliance, a non‑profit organization that reports revenue from individual donors  and corporations including Greenwich Biosciences, GW Pharma, Mallinckrodt,  Nobelpharma, Novartis, Ovid, UCB, and Upsher‑Smith. DAK reports grants from the  National Institutes of Health (NINDS) during the conduct of the study as well as  the personal fees from Novartis Pharmaceuticals, personal fees from Greenwich  Bioscience, grants from Marinus Pharmaceuticals, personal fees from Nobelpharma  America, personal fees from REGENXBIO, and grants and non‑financial support from  TSC Alliance outside the submitted work. MS reports grant support from Novartis,  Biogen, Astellas, Aeovian, Bridgebio, and Aucta and has served on Scientific  Advisory Boards for Novartis, Roche, Regenxbio, SpringWorks Therapeutics, Jaguar  Therapeutics, and Alkermes. ACJ was on the scientific advisory group of the TOSCA  international disease registry sponsored by Novartis and has provided consultancy  to GW Pharma. The remaining authors declared no competing interests. Index. décimale : PER Périodiques Résumé : BACKGROUND: Tuberous sclerosis complex (TSC) is associated with a wide range of physical manifestations for which international clinical recommendations for diagnosis and management have been established. TSC is, however, also associated with a wide range of TSC-Associated Neuropsychiatric Disorders (TAND) that are typically under-identified and under-treated yet associated with a profound burden of disease. The contemporary evidence base for the identification and treatment of TAND is much more limited and, to date, consensus recommendations for the diagnosis and management of TAND have also been limited and non-specific. METHODS: The TANDem project was launched with an international, interdisciplinary, and participatory consortium of 24 individuals, including TSC family representatives, from all World Health Organization (WHO) regions but one. One of the aims of the TANDem project was to generate consensus recommendations for the identification and treatment of TAND. At the time of this project, no internationally adopted standard methodology and methodological checklists existed for the generation of clinical practice recommendations. We therefore developed our own systematic procedure for evidence review and consensus-building to generate evidence-informed consensus recommendations of relevance to the global TSC community. RESULTS: At the heart of the consensus recommendations are ten core principles surrounded by cluster-specific recommendations for each of the seven natural TAND clusters identified in the literature (autism-like, dysregulated behavior, eat/sleep, mood/anxiety, neuropsychological, overactive/impulsive, and scholastic) and a set of wraparound psychosocial cluster recommendations. The overarching recommendation is to "screen" for TAND at least annually, to "act" using appropriate next steps for evaluation and treatment, and to "repeat" the process to ensure early identification and early intervention with the most appropriate biological, psychological, and social evidence-informed approaches to support individuals with TSC and their families. CONCLUSIONS: The consensus recommendations should provide a systematic framework to approach the identification and treatment of TAND for health, educational, social care teams and families who live with TSC. To ensure global dissemination and implementation of these recommendations, partnerships with the international TSC community will be important. One of these steps will include the generation of a "TAND toolkit" of "what to seek" and "what to do" when difficulties are identified in TAND clusters. En ligne : https://dx.doi.org/10.1186/s11689-023-09500-1 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=575

Natural clusters of tuberous sclerosis complex (TSC)-associated neuropsychiatric disorders (TAND): new findings from the TOSCA TAND research project / Petrus J. DE VRIES in Journal of Neurodevelopmental Disorders, 12 (2020)  

Public ISBD [article]  inJournal of Neurodevelopmental Disorders > 12 (2020) Titre : Natural clusters of tuberous sclerosis complex (TSC)-associated neuropsychiatric disorders (TAND): new findings from the TOSCA TAND research project Type de document : texte imprimé Auteurs : Petrus J. DE VRIES, Auteur ; Elena BELOUSOVA, Auteur ; Mirjana P. BENEDIK, Auteur ; Tom CARTER, Auteur ; Vincent COTTIN, Auteur ; Paolo CURATOLO, Auteur ; Lisa D'AMATO, Auteur ; Guillaume BEURE D'AUGÈRES, Auteur ; José C. FERREIRA, Auteur ; Martha FEUCHT, Auteur ; Carla FLADROWSKI, Auteur ; Christoph HERTZBERG, Auteur ; Sergiusz JOZWIAK, Auteur ; John A. LAWSON, Auteur ; Alfons MACAYA, Auteur ; Ruben MARQUES, Auteur ; Rima NABBOUT, Auteur ; Finbar O'CALLAGHAN, Auteur ; Jiong QIN, Auteur ; Valentin SANDER, Auteur ; Matthias SAUTER, Auteur ; Seema SHAH, Auteur ; Yukitoshi TAKAHASHI, Auteur ; Renaud TOURAINE, Auteur ; Sotiris YOUROUKOS, Auteur ; Bernard ZONNENBERG, Auteur ; J Chris KINGSWOOD, Auteur ; Anna C. JANSEN, Auteur ; TOSCA CONSORTIUM AND TOSCA INVESTIGATORS, Auteur Langues : Anglais (eng) Mots-clés : Autism Spectrum Disorder/epidemiology/etiology  Checklist  Cognitive Dysfunction  Feasibility Studies  Female  Humans  Male  Tuberous Sclerosis/complications/epidemiology  Asd  Cluster analysis  Factor analysis  Natural TAND clusters  Neuropsychiatric  Registry  Tand  Tosca  Tuberous sclerosis complex  AM, SY, MPB, BZ, and ACJ received honoraria and travel support from Novartis. VC  received personal fees for consulting  lecture fees and travel from Actelion,  Bayer, Biogen Idec, Boehringer Ingelheim, Gilead, GSK, MSD, Novartis, Pfizer,  Roche, and Sanofi  grants from Actelion, Boehringer Ingelheim, GSK, Pfizer, and  Roche  and personal fees for developing educational material from Boehringer  Ingelheim and Roche. PJdV has been on the steering group of the EXIST-1, 2, and 3  studies sponsored by Novartis and co-PI on two investigator-initiated studies  part-funded by Novartis. RN received grant support, paid to her institution, from  Eisai and lecture fees from Nutricia, Eisai, Advicenne, and GW Pharma. YT  received personal fees from Novartis for lecture and for copyright of referential  figures from the journals and grant from the Japanese government for intractable  epilepsy research. SJ was partly financed by the EC Seventh Framework Programme  (FP7/2007-2013  EPISTOP, grant agreement no. 602391), the Polish Ministerial  funds for science (years 2013–2018) for the implementation of international  co-financed project, and the grant EPIMARKER of the Polish National Center for  Research and Development No. STRATEGMED3/306306/4/2016. JCK, PC, CH, JAL, and JQ  received research grants from Novartis. RM and SS are employees of Novartis. LD’A  was an employee of Novartis at the time of manuscript concept approval. VS  reported no conflict of interest. Index. décimale : PER Périodiques Résumé : BACKGROUND: Tuberous sclerosis complex (TSC)-associated neuropsychiatric disorders (TAND) have unique, individual patterns that pose significant challenges for diagnosis, psycho-education, and intervention planning. A recent study suggested that it may be feasible to use TAND Checklist data and data-driven methods to generate natural TAND clusters. However, the study had a small sample size and data from only two countries. Here, we investigated the replicability of identifying natural TAND clusters from a larger and more diverse sample from the TOSCA study. METHODS: As part of the TOSCA international TSC registry study, this embedded research project collected TAND Checklist data from individuals with TSC. Correlation coefficients were calculated for TAND variables to generate a correlation matrix. Hierarchical cluster and factor analysis methods were used for data reduction and identification of natural TAND clusters. RESULTS: A total of 85 individuals with TSC (female:male, 40:45) from 7 countries were enrolled. Cluster analysis grouped the TAND variables into 6 clusters: a scholastic cluster (reading, writing, spelling, mathematics, visuo-spatial difficulties, disorientation), a hyperactive/impulsive cluster (hyperactivity, impulsivity, self-injurious behavior), a mood/anxiety cluster (anxiety, depressed mood, sleep difficulties, shyness), a neuropsychological cluster (attention/concentration difficulties, memory, attention, dual/multi-tasking, executive skills deficits), a dysregulated behavior cluster (mood swings, aggressive outbursts, temper tantrums), and an autism spectrum disorder (ASD)-like cluster (delayed language, poor eye contact, repetitive behaviors, unusual use of language, inflexibility, difficulties associated with eating). The natural clusters mapped reasonably well onto the six-factor solution generated. Comparison between cluster and factor solutions from this study and the earlier feasibility study showed significant similarity, particularly in cluster solutions. CONCLUSIONS: Results from this TOSCA research project in an independent international data set showed that the combination of cluster analysis and factor analysis may be able to identify clinically meaningful natural TAND clusters. Findings were remarkably similar to those identified in the earlier feasibility study, supporting the potential robustness of these natural TAND clusters. Further steps should include examination of larger samples, investigation of internal consistency, and evaluation of the robustness of the proposed natural clusters. En ligne : https://dx.doi.org/10.1186/s11689-020-09327-0 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=573 [article] Natural clusters of tuberous sclerosis complex (TSC)-associated neuropsychiatric disorders (TAND): new findings from the TOSCA TAND research project [texte imprimé] / Petrus J. DE VRIES, Auteur ; Elena BELOUSOVA, Auteur ; Mirjana P. BENEDIK, Auteur ; Tom CARTER, Auteur ; Vincent COTTIN, Auteur ; Paolo CURATOLO, Auteur ; Lisa D'AMATO, Auteur ; Guillaume BEURE D'AUGÈRES, Auteur ; José C. FERREIRA, Auteur ; Martha FEUCHT, Auteur ; Carla FLADROWSKI, Auteur ; Christoph HERTZBERG, Auteur ; Sergiusz JOZWIAK, Auteur ; John A. LAWSON, Auteur ; Alfons MACAYA, Auteur ; Ruben MARQUES, Auteur ; Rima NABBOUT, Auteur ; Finbar O'CALLAGHAN, Auteur ; Jiong QIN, Auteur ; Valentin SANDER, Auteur ; Matthias SAUTER, Auteur ; Seema SHAH, Auteur ; Yukitoshi TAKAHASHI, Auteur ; Renaud TOURAINE, Auteur ; Sotiris YOUROUKOS, Auteur ; Bernard ZONNENBERG, Auteur ; J Chris KINGSWOOD, Auteur ; Anna C. JANSEN, Auteur ; TOSCA CONSORTIUM AND TOSCA INVESTIGATORS, Auteur. Langues : Anglais (eng) in Journal of Neurodevelopmental Disorders > 12 (2020) Mots-clés : Autism Spectrum Disorder/epidemiology/etiology  Checklist  Cognitive Dysfunction  Feasibility Studies  Female  Humans  Male  Tuberous Sclerosis/complications/epidemiology  Asd  Cluster analysis  Factor analysis  Natural TAND clusters  Neuropsychiatric  Registry  Tand  Tosca  Tuberous sclerosis complex  AM, SY, MPB, BZ, and ACJ received honoraria and travel support from Novartis. VC  received personal fees for consulting  lecture fees and travel from Actelion,  Bayer, Biogen Idec, Boehringer Ingelheim, Gilead, GSK, MSD, Novartis, Pfizer,  Roche, and Sanofi  grants from Actelion, Boehringer Ingelheim, GSK, Pfizer, and  Roche  and personal fees for developing educational material from Boehringer  Ingelheim and Roche. PJdV has been on the steering group of the EXIST-1, 2, and 3  studies sponsored by Novartis and co-PI on two investigator-initiated studies  part-funded by Novartis. RN received grant support, paid to her institution, from  Eisai and lecture fees from Nutricia, Eisai, Advicenne, and GW Pharma. YT  received personal fees from Novartis for lecture and for copyright of referential  figures from the journals and grant from the Japanese government for intractable  epilepsy research. SJ was partly financed by the EC Seventh Framework Programme  (FP7/2007-2013  EPISTOP, grant agreement no. 602391), the Polish Ministerial  funds for science (years 2013–2018) for the implementation of international  co-financed project, and the grant EPIMARKER of the Polish National Center for  Research and Development No. STRATEGMED3/306306/4/2016. JCK, PC, CH, JAL, and JQ  received research grants from Novartis. RM and SS are employees of Novartis. LD’A  was an employee of Novartis at the time of manuscript concept approval. VS  reported no conflict of interest. Index. décimale : PER Périodiques Résumé : BACKGROUND: Tuberous sclerosis complex (TSC)-associated neuropsychiatric disorders (TAND) have unique, individual patterns that pose significant challenges for diagnosis, psycho-education, and intervention planning. A recent study suggested that it may be feasible to use TAND Checklist data and data-driven methods to generate natural TAND clusters. However, the study had a small sample size and data from only two countries. Here, we investigated the replicability of identifying natural TAND clusters from a larger and more diverse sample from the TOSCA study. METHODS: As part of the TOSCA international TSC registry study, this embedded research project collected TAND Checklist data from individuals with TSC. Correlation coefficients were calculated for TAND variables to generate a correlation matrix. Hierarchical cluster and factor analysis methods were used for data reduction and identification of natural TAND clusters. RESULTS: A total of 85 individuals with TSC (female:male, 40:45) from 7 countries were enrolled. Cluster analysis grouped the TAND variables into 6 clusters: a scholastic cluster (reading, writing, spelling, mathematics, visuo-spatial difficulties, disorientation), a hyperactive/impulsive cluster (hyperactivity, impulsivity, self-injurious behavior), a mood/anxiety cluster (anxiety, depressed mood, sleep difficulties, shyness), a neuropsychological cluster (attention/concentration difficulties, memory, attention, dual/multi-tasking, executive skills deficits), a dysregulated behavior cluster (mood swings, aggressive outbursts, temper tantrums), and an autism spectrum disorder (ASD)-like cluster (delayed language, poor eye contact, repetitive behaviors, unusual use of language, inflexibility, difficulties associated with eating). The natural clusters mapped reasonably well onto the six-factor solution generated. Comparison between cluster and factor solutions from this study and the earlier feasibility study showed significant similarity, particularly in cluster solutions. CONCLUSIONS: Results from this TOSCA research project in an independent international data set showed that the combination of cluster analysis and factor analysis may be able to identify clinically meaningful natural TAND clusters. Findings were remarkably similar to those identified in the earlier feasibility study, supporting the potential robustness of these natural TAND clusters. Further steps should include examination of larger samples, investigation of internal consistency, and evaluation of the robustness of the proposed natural clusters. En ligne : https://dx.doi.org/10.1186/s11689-020-09327-0 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=573

The research landscape of tuberous sclerosis complex-associated neuropsychiatric disorders (TAND)-a comprehensive scoping review / Stephanie VANCLOOSTER in Journal of Neurodevelopmental Disorders, 14 (2022)  

Public ISBD [article]  inJournal of Neurodevelopmental Disorders > 14 (2022) Titre : The research landscape of tuberous sclerosis complex-associated neuropsychiatric disorders (TAND)-a comprehensive scoping review Type de document : texte imprimé Auteurs : Stephanie VANCLOOSTER, Auteur ; Stacey BISSELL, Auteur ; Agnies M. VAN EEGHEN, Auteur ; Nola CHAMBERS, Auteur ; Liesbeth DE WAELE, Auteur ; Anna W. BYARS, Auteur ; Jamie K. CAPAL, Auteur ; Sebastián CUKIER, Auteur ; Peter DAVIS, Auteur ; Jennifer FLINN, Auteur ; Sugnet GARDNER-LUBBE, Auteur ; Tanjala GIPSON, Auteur ; Tosca-Marie HEUNIS, Auteur ; Dena HOOK, Auteur ; J. Christopher KINGSWOOD, Auteur ; Darcy A. KRUEGER, Auteur ; Aubrey J. KUMM, Auteur ; Mustafa SAHIN, Auteur ; Eva SCHOETERS, Auteur ; Catherine SMITH, Auteur ; Shoba SRIVASTAVA, Auteur ; Megumi TAKEI, Auteur ; Robert WALTEREIT, Auteur ; Anna C. JANSEN, Auteur ; Petrus J. DE VRIES, Auteur Langues : Anglais (eng) Mots-clés : Adolescent  Aged  Autism Spectrum Disorder  Cohort Studies  Humans  Tuberous Sclerosis/complications/psychology  Autism  Behaviour  Intellectual  Neuropsychological  Psychiatric  Psychosocial  Scholastic  Scoping review  TSC-associated neuropsychiatric disorders  Tuberous sclerosis complex  syndromes, including TSC. PD receives partial salary support from the NIH for  participation in studies related to TSC, as well as from Aucta Pharmaceuticals  for a study of topical sirolimus for facial angiofibromas in TSC and Marinus  Pharmaceuticals for a study of ganaxolone for TSC-related epilepsy. DAK reports  grants from National Institutes of Health (NINDS) during the conduct of the study  as well as the personal fees from Novartis Pharmaceuticals, personal fees from  Greenwich Bioscience, grants from Marinus Pharmaceuticals, personal fees from  Nobelpharma America, personal fees from REGENXBIO, and grants and non-financial  support from TSC Alliance outside the submitted work. CS receives salary support  from the TSC Alliance, a non-profit organisation which reports revenue from  individual donors and corporations including Greenwich Biosciences, GW Pharma,  Mallinckrodt, Nobelpharma, Novartis, Ovid, UCB and Upsher-Smith. PJdV was a study  steering committee member of three phase III trials sponsored by Novartis. He and  AJ were also on the scientific advisory group of the TOSCA international disease  registry sponsored by Novartis. MS reports grant support from Novartis, Biogen,  Astellas, Aeovian, Bridgebio and Aucta, and has served on Scientific Advisory  Boards for Novartis, Roche, Regenxbio, SpringWorks Therapeutics, Jaguar  Therapeutics and Alkermes. Index. décimale : PER Périodiques Résumé : BACKGROUND: Tuberous sclerosis complex (TSC)-associated neuropsychiatric disorders (TAND) is an umbrella term for the behavioural, psychiatric, intellectual, academic, neuropsychological and psychosocial manifestations of TSC. Although TAND affects 90% of individuals with TSC during their lifetime, these manifestations are relatively under-assessed, under-treated and under-researched. We performed a comprehensive scoping review of all TAND research to date (a) to describe the existing TAND research landscape and (b) to identify knowledge gaps to guide future TAND research. METHODS: The study was conducted in accordance with stages outlined within the Arksey and O'Malley scoping review framework. Ten research questions relating to study characteristics, research design and research content of TAND levels and clusters were examined. RESULTS: Of the 2841 returned searches, 230 articles published between 1987 and 2020 were included (animal studies = 30, case studies = 47, cohort studies = 153), with more than half published since the term TAND was coined in 2012 (118/230; 51%). Cohort studies largely involved children and/or adolescents (63%) as opposed to older adults (16%). Studies were represented across 341 individual research sites from 45 countries, the majority from the USA (89/341; 26%) and the UK (50/341; 15%). Only 48 research sites (14%) were within low-middle income countries (LMICs). Animal studies and case studies were of relatively high/high quality, but cohort studies showed significant variability. Of the 153 cohort studies, only 16 (10%) included interventions. None of these were non-pharmacological, and only 13 employed remote methodologies (e.g. telephone interviews, online surveys). Of all TAND clusters, the autism spectrum disorder-like cluster was the most widely researched (138/230; 60%) and the scholastic cluster the least (53/200; 27%). CONCLUSIONS: Despite the recent increase in TAND research, studies that represent participants across the lifespan, LMIC research sites and non-pharmacological interventions were identified as future priorities. The quality of cohort studies requires improvement, to which the use of standardised direct behavioural assessments may contribute. In human studies, the academic level in particular warrants further investigation. Remote technologies could help to address many of the TAND knowledge gaps identified. En ligne : https://dx.doi.org/10.1186/s11689-022-09423-3 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=574 [article] The research landscape of tuberous sclerosis complex-associated neuropsychiatric disorders (TAND)-a comprehensive scoping review [texte imprimé] / Stephanie VANCLOOSTER, Auteur ; Stacey BISSELL, Auteur ; Agnies M. VAN EEGHEN, Auteur ; Nola CHAMBERS, Auteur ; Liesbeth DE WAELE, Auteur ; Anna W. BYARS, Auteur ; Jamie K. CAPAL, Auteur ; Sebastián CUKIER, Auteur ; Peter DAVIS, Auteur ; Jennifer FLINN, Auteur ; Sugnet GARDNER-LUBBE, Auteur ; Tanjala GIPSON, Auteur ; Tosca-Marie HEUNIS, Auteur ; Dena HOOK, Auteur ; J. Christopher KINGSWOOD, Auteur ; Darcy A. KRUEGER, Auteur ; Aubrey J. KUMM, Auteur ; Mustafa SAHIN, Auteur ; Eva SCHOETERS, Auteur ; Catherine SMITH, Auteur ; Shoba SRIVASTAVA, Auteur ; Megumi TAKEI, Auteur ; Robert WALTEREIT, Auteur ; Anna C. JANSEN, Auteur ; Petrus J. DE VRIES, Auteur. Langues : Anglais (eng) in Journal of Neurodevelopmental Disorders > 14 (2022) Mots-clés : Adolescent  Aged  Autism Spectrum Disorder  Cohort Studies  Humans  Tuberous Sclerosis/complications/psychology  Autism  Behaviour  Intellectual  Neuropsychological  Psychiatric  Psychosocial  Scholastic  Scoping review  TSC-associated neuropsychiatric disorders  Tuberous sclerosis complex  syndromes, including TSC. PD receives partial salary support from the NIH for  participation in studies related to TSC, as well as from Aucta Pharmaceuticals  for a study of topical sirolimus for facial angiofibromas in TSC and Marinus  Pharmaceuticals for a study of ganaxolone for TSC-related epilepsy. DAK reports  grants from National Institutes of Health (NINDS) during the conduct of the study  as well as the personal fees from Novartis Pharmaceuticals, personal fees from  Greenwich Bioscience, grants from Marinus Pharmaceuticals, personal fees from  Nobelpharma America, personal fees from REGENXBIO, and grants and non-financial  support from TSC Alliance outside the submitted work. CS receives salary support  from the TSC Alliance, a non-profit organisation which reports revenue from  individual donors and corporations including Greenwich Biosciences, GW Pharma,  Mallinckrodt, Nobelpharma, Novartis, Ovid, UCB and Upsher-Smith. PJdV was a study  steering committee member of three phase III trials sponsored by Novartis. He and  AJ were also on the scientific advisory group of the TOSCA international disease  registry sponsored by Novartis. MS reports grant support from Novartis, Biogen,  Astellas, Aeovian, Bridgebio and Aucta, and has served on Scientific Advisory  Boards for Novartis, Roche, Regenxbio, SpringWorks Therapeutics, Jaguar  Therapeutics and Alkermes. Index. décimale : PER Périodiques Résumé : BACKGROUND: Tuberous sclerosis complex (TSC)-associated neuropsychiatric disorders (TAND) is an umbrella term for the behavioural, psychiatric, intellectual, academic, neuropsychological and psychosocial manifestations of TSC. Although TAND affects 90% of individuals with TSC during their lifetime, these manifestations are relatively under-assessed, under-treated and under-researched. We performed a comprehensive scoping review of all TAND research to date (a) to describe the existing TAND research landscape and (b) to identify knowledge gaps to guide future TAND research. METHODS: The study was conducted in accordance with stages outlined within the Arksey and O'Malley scoping review framework. Ten research questions relating to study characteristics, research design and research content of TAND levels and clusters were examined. RESULTS: Of the 2841 returned searches, 230 articles published between 1987 and 2020 were included (animal studies = 30, case studies = 47, cohort studies = 153), with more than half published since the term TAND was coined in 2012 (118/230; 51%). Cohort studies largely involved children and/or adolescents (63%) as opposed to older adults (16%). Studies were represented across 341 individual research sites from 45 countries, the majority from the USA (89/341; 26%) and the UK (50/341; 15%). Only 48 research sites (14%) were within low-middle income countries (LMICs). Animal studies and case studies were of relatively high/high quality, but cohort studies showed significant variability. Of the 153 cohort studies, only 16 (10%) included interventions. None of these were non-pharmacological, and only 13 employed remote methodologies (e.g. telephone interviews, online surveys). Of all TAND clusters, the autism spectrum disorder-like cluster was the most widely researched (138/230; 60%) and the scholastic cluster the least (53/200; 27%). CONCLUSIONS: Despite the recent increase in TAND research, studies that represent participants across the lifespan, LMIC research sites and non-pharmacological interventions were identified as future priorities. The quality of cohort studies requires improvement, to which the use of standardised direct behavioural assessments may contribute. In human studies, the academic level in particular warrants further investigation. Remote technologies could help to address many of the TAND knowledge gaps identified. En ligne : https://dx.doi.org/10.1186/s11689-022-09423-3 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=574

---

1 (1 - 4 / 4) Par page : 25 50 100 200